Shanghai Haohai Biological Technology Bilan de santé
Santé financière contrôle des critères 5/6
Shanghai Haohai Biological Technology possède un total de capitaux propres de CN¥6.0B et une dette totale de CN¥423.7M, ce qui porte son ratio d'endettement à 7%. Son actif total et son passif total sont CN¥7.2B et de CN¥1.2B. L'EBIT de Shanghai Haohai Biological Technology est CN¥404.8M ce qui fait que son ratio de couverture des intérêts -6.4. Elle dispose de liquidités et de placements à court terme de CN¥2.7B.
Informations clés
7.0%
Ratio d'endettement
CN¥423.70m
Dette
| Ratio de couverture des intérêts | -6.4x |
| Argent liquide | CN¥2.69b |
| Fonds propres | CN¥6.03b |
| Total du passif | CN¥1.21b |
| Total des actifs | CN¥7.25b |
Mises à jour récentes de la santé financière
We Think Shanghai Haohai Biological Technology (HKG:6826) Can Manage Its Debt With Ease
Jul 25
Shanghai Haohai Biological Technology (HKG:6826) Seems To Use Debt Rather Sparingly
Apr 17Is Shanghai Haohai Biological Technology (HKG:6826) Using Too Much Debt?
Nov 14Shanghai Haohai Biological Technology (HKG:6826) Has A Pretty Healthy Balance Sheet
Jul 28We Think Shanghai Haohai Biological Technology (HKG:6826) Can Stay On Top Of Its Debt
Mar 09These 4 Measures Indicate That Shanghai Haohai Biological Technology (HKG:6826) Is Using Debt Reasonably Well
Nov 25Recent updates
We Think Shanghai Haohai Biological Technology (HKG:6826) Can Manage Its Debt With Ease
Jul 25Why We Think Shanghai Haohai Biological Technology Co., Ltd.'s (HKG:6826) CEO Compensation Is Not Excessive At All
May 22Shanghai Haohai Biological Technology (HKG:6826) Seems To Use Debt Rather Sparingly
Apr 17Are Shanghai Haohai Biological Technology Co., Ltd. (HKG:6826) Investors Paying Above The Intrinsic Value?
Feb 12Is Shanghai Haohai Biological Technology (HKG:6826) Using Too Much Debt?
Nov 14Shanghai Haohai Biological Technology (HKG:6826) Has A Pretty Healthy Balance Sheet
Jul 28We Think Shanghai Haohai Biological Technology (HKG:6826) Can Stay On Top Of Its Debt
Mar 09These 4 Measures Indicate That Shanghai Haohai Biological Technology (HKG:6826) Is Using Debt Reasonably Well
Nov 25Shanghai Haohai Biological Technology (HKG:6826) Has A Pretty Healthy Balance Sheet
Jul 30Shanghai Haohai Biological Technology Co., Ltd.'s (HKG:6826) Intrinsic Value Is Potentially 96% Above Its Share Price
May 08Is Shanghai Haohai Biological Technology (HKG:6826) Using Too Much Debt?
Apr 19Analyst Forecasts Just Became More Bearish On Shanghai Haohai Biological Technology Co., Ltd. (HKG:6826)
Mar 04Shanghai Haohai Biological Technology Co., Ltd. Just Missed Earnings - But Analysts Have Updated Their Models
Mar 03Is Shanghai Haohai Biological Technology (HKG:6826) A Risky Investment?
Jan 10Shanghai Haohai Biological Technology (HKG:6826) Seems To Use Debt Rather Sparingly
Oct 08Here's Why Shanghai Haohai Biological Technology (HKG:6826) Can Manage Its Debt Responsibly
Jul 07Analysts Have Just Cut Their Shanghai Haohai Biological Technology Co., Ltd. (HKG:6826) Revenue Estimates By 14%
May 27These 4 Measures Indicate That Shanghai Haohai Biological Technology (HKG:6826) Is Using Debt Reasonably Well
Apr 04Investors Who Bought Shanghai Haohai Biological Technology (HKG:6826) Shares A Year Ago Are Now Up 58%
Mar 16Analyse de la situation financière
Passif à court terme: Les actifs à court terme de 6826 ( CN¥3.7B ) dépassent ses passifs à court terme ( CN¥861.5M ).
Passif à long terme: Les actifs à court terme de 6826 ( CN¥3.7B ) dépassent ses passifs à long terme ( CN¥350.6M ).
Historique et analyse du ratio d'endettement
Niveau d'endettement: 6826 dispose de plus de liquidités que de sa dette totale.
Réduire la dette: Le ratio d'endettement de 6826 est passé de 0.7% à 7% au cours des 5 dernières années.
Couverture de la dette: La dette de 6826 est bien couverte par le flux de trésorerie opérationnel ( 159% ).
Couverture des intérêts: 6826 gagne plus d'intérêts qu'il n'en paie, donc la couverture des paiements d'intérêts n'est pas un problème.